Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May 11:15:393.
doi: 10.1186/s12885-015-1426-3.

Increased risk of second primary malignancies following uterine cancer: a population-based study in Taiwan over a 30-year period

Kuan-Der Lee  1 , Chao-Yu Chen  2 , Huei-Jean Huang  3 , Ting-Yao Wang  4 , David Teng  5 , Shih-Hao Huang  6 , Chyong-Huey Lai  7 , Min-Chi Chen  8
Affiliations

Increased risk of second primary malignancies following uterine cancer: a population-based study in Taiwan over a 30-year period

Kuan-Der Lee et al. BMC Cancer. .

Abstract

Background: Previous studies assessing second primary malignancies (SPMs) after uterine cancer have been conducted in Western populations with conflicting results. This study aimed to define the incidence and risk of SPMs in Taiwanese patients with an initial diagnosis of uterine cancer.

Methods: Using population-based data from the Taiwan Cancer Registry for the period 1979-2008, we quantified standardized incidence ratios (SIRs) among 11,571 women with an initial diagnosis of uterine cancer.

Results: Among the 11,571 women, 555 (4.80%) developed at least one SPM during 69,987 person-years of follow-up. There was a 71% increased risk of SPM following uterine cancer (SIR=1.71, 95% CI, 1.57-1.86), with higher risks in the vagina/vulva (SIR=9.06), small intestine (SIR=8.45), ovary (SIR=4.15), urinary bladder (SIR=2.31), kidney (SIR=2.24), colorectum (SIR=2.24), lung (SIR=1.96), and breast (SIR=1.43). The risk of SPM was found to be the highest within the first 5 years after diagnosis of uterine cancer, with surveillance bias possibly contributing to the extremely high risk observed in the first follow-up year. The overall risk and pattern of SPM development observed in this study differed from those previously reported in Western populations, possibly because of the methodology and shorter follow-up period employed in this study. The cumulative incidence of SPMs was significantly higher in older patients (≥50 years) than in younger patients (P<0.001).

Conclusions: To our knowledge, this is the first study in an Asian population to report 71% increased risk in SPMs in women previously diagnosed with uterine cancer. A younger age at diagnosis of uterine cancer conferred an increased risk of second malignancies, and SPMs worsened survivorship in patients who survived uterine cancer.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Cumulative incidence rates of all the second cancers after uterine cancer stratified by age
Fig. 2
Fig. 2
(a): Survival of all the patients with uterine cancer stratified by age at diagnosis of uterine cancer; (b): survival after second primary cancers stratified by age
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi: 10.3322/caac.20107. - DOI - PubMed
    1. Duncan ME, Seagroatt V, Goldacre MJ. Cancer of the body of the uterus: trends in mortality and incidence in England, 1985-2008. BJOG. 2012;119:333–9. doi: 10.1111/j.1471-0528.2011.03201.x. - DOI - PubMed
    1. Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012;120:383–97. doi: 10.1097/AOG.0b013e3182605bf1. - DOI - PubMed
    1. Lin CH, Chen YC, Chiang CJ, Lu YS, Kuo KT, Huang CS, et al. The emerging epidemic of estrogen-related cancers in young women in a developing Asian country. Int J Cancer. 2012;130:2629–37. doi: 10.1002/ijc.26249. - DOI - PubMed
    1. Ushijima K. Current status of gynecologic cancer in Japan. J Gynecol Oncol. 2009;20:67–71. doi: 10.3802/jgo.2009.20.2.67. - DOI - PMC - PubMed

Publication types